Clinical trials: Neuroepithelial Tumor
Neuroblastoma
High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)
This is a randomized study of the European SIOP Neuroblastoma Group (SIOPEN) in high-risk neuroblastoma (stages 2, 3, 4 and 4s MYCN-amplified neuroblastoma, stage 4 MYCN non amplified > 12 months at diagnosis).
- Trial name
- NCT01704716
- Testing
- Vincristine, Aldesleukin, ch14.18/CHO
- Where
- 126 sites in Australia, Austria and 18 more
- Volunteers
- 3,300 people
- Sponsor
- St. Anna Kinderkrebsforschung
Brain Cancer, Brain Neoplasm
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
Glioblastoma (GBM) and gliosarcoma (GS) are the most common and aggressive forms of malignant brain tumor in adults and can be resistant to conventional therapies.
- Conditions
- Brain Cancer, Brain Neoplasm, Glioma, Glioblastoma
- Trial name
- CAPTIVE (NCT02798406)
- Testing
- DNX-2401, pembrolizumab
- Where
- 15 sites in United States, Canada
- Volunteers
- 49 people
- Sponsor
- DNAtrix, Inc.
Recurrent Glioblastoma, IDH-Wildtype
Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma
This phase II trial compares the safety, side effects and effectiveness of atezolizumab with tiragolumab to atezolizumab alone in treating patients with glioblastoma that has come back after a period of improvement (recurrent).
- Trial name
- NCT06328036
- Testing
- Atezolizumab, Biospecimen Collection, Magnetic Resonance Imaging
- Sponsor
- National Cancer Institute (NCI)
Neuroblastoma
A Study on the Efficacy of GD2-CAR T Cells in the Treatment of Neuroblastoma
Neuroblastoma (NB) is a malignant tumor of the sympathetic nervous system.Chemotherapy and autologous hematopoietic stem cell transplantation are the main treatments for neuroblastoma, and the prognosis of patients with high-risk…
- Trial name
- NCT06684639
- Testing
- GD2-CAR-T cell
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The General Hospital of Western Theater Command
Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases
This early phase I trial tests the use of a radioactive tracer (a drug that is visible during an imaging test) known as 18F-FMAU, for imaging with positron emission tomography/computed tomography (PET/CT) in patients with brain…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Glioma, Malignant Brain Neoplasm
- Trial name
- NCT04752267
- Testing
- Computed Tomography, 18F-FMAU, Multiparametric Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Southern California
Neuroblastoma
A Pilot Study on ALK Gene Mutations in Neuroblastoma
Neuroblastoma (NB) originates from the sympathetic nervous system and is one of the most common cancers in infants and children.
- Trial name
- NCT01986595
- Where
- Taiwan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Neuroblastoma
ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma
The purpose of this study is to compare the pharmacokinetics (blood levels) and safety of chimeric (ch) 14.18 manufactured by two independent drug makers (United Therapeutics [UTC] or the National Cancer Institute [NCI]).
- Trial name
- NCT01592045
- Testing
- ch14.18 -NCI, ch14.18-UTC, Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
- Where
- 13 sites in United States
- Volunteers
- 28 people
- Sponsor
- United Therapeutics
Neuroblastoma
131I-MIBG With Myeloablative Chemotherapy and Autologous Stem Cell Transplantation for the Treatment of High-risk Neuroblastoma
This trial is studying how well iodine I 131 metaiodobenzylguanidine together with combination chemotherapy works in treating patients who are undergoing an autologous peripheral stem cell for high risk or relapsed neuroblastoma.
- Trial name
- NCT00798148
- Testing
- 131I-MIBG , Etoposide, Melphalan, Carboplatin, Autologous Peripheral Stem Cell Transplantation
- Where
- 2 sites in Iran
- Volunteers
- 10 people
- Sponsor
- Tehran University of Medical Sciences
Neuroblastoma
Chemotherapy and Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00017225
- Testing
- filgrastim, carboplatin, cisplatin
- Where
- 94 sites in Germany, Netherlands and 1 more
- Sponsor
- German Society for Pediatric Oncology and Hematology GPOH gGmbH
Constitutional Mismatch Repair Deficiency Syndrome, Hematopoietic and Lymphoid Cell Neoplasm
Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study
This phase Ib trial investigates the side effects of the combination of nivolumab and ipilimumab, and to see how well they work in treating patients with cancers that have come back (relapsed) or does not respond to treatment…
- Conditions
- Constitutional Mismatch Repair Deficiency Syndrome, Hematopoietic and Lymphoid Cell Neoplasm, Lynch Syndrome, Recurrent Lymphoma
- Trial name
- NCT04500548
- Testing
- Biospecimen Collection, Ipilimumab, Nivolumab
- Where
- 9 sites in United States, Canada
- Sponsor
- National Cancer Institute (NCI)
Glioma Glioblastoma Multiforme
[18F]Fluciclovine in Post-treatment Glioblastoma ( Axumin )
Subjects with histologically proven glioblastoma (GBM) who are suspected to have progression and are candidates for a surgical resection according to standard of care may be eligible for this study.
- Trial name
- Axumin (NCT03990285)
- Testing
- Axumin, Intravenous Solution
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Ali Nabavizadeh
Brain and Central Nervous System Tumors
Biological Therapy and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Biological therapies such as poly-ICLC use different ways to stimulate the immune system and stop tumor cells from growing. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- Poly-ICLC (NCT00052715)
- Testing
- poly ICLC
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Glioma
A Study in Subjects With Recurrent Malignant Glioma
An open-label phase 2, multicenter study in participants with recurrent malignant glioma.
- Trial name
- NCT01137604
- Testing
- Lenvatinib, Bevacizumab
- Where
- 5 sites in United States, Canada
- Volunteers
- 151 people
- Sponsor
- Eisai Inc.
Acute Myeloid Leukemia, Acute Lymphoid Leukemia
G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor
The purpose of this study is to explore the effect of G-CSF combination with GM-CSF on prevention and treatment of infection in children with malignant tumor.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Lymphoma, Neuroblastoma
- Trial name
- NCT02933333
- Testing
- GM-CSF, G-CSF, GM-CSF and G-CSF
- Where
- 7 sites in China
- Volunteers
- 405 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Glioblastoma
Anlotinib Combined With Dose-dense Temozolomide for the First Recurrent or Progressive Glioblastoma After STUPP Regimen
Currently,6 cycles of Temozolomide adjuvant chemotherapy after concurrent radiotherapy and Temozolomide chemotherapy(STUPP regimen)for newly diagnosed postoperative GBM can increase the 2-year and 5-year overall survival rates of…
- Trial name
- NCT04547855
- Testing
- anlotinib combined with dose-dense temozolomide
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Yonggao Mou
Glioblastoma
Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients
The primary purpose of the study is to evaluate the efficacy and safety of supra-early post-surgery chemotherapy versus standard TEMODAL® regimen in treatment of patients with newly diagnosed glioblastoma multiforme.
- Trial name
- NCT02520635
- Testing
- supra-early TEMODAL® chemotherapy, standard TEMODAL® chemotherapy, Radiotherapy 60Gy
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Beijing Tiantan Hospital
Glioblastoma Multiforme
Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM)
Conduct a multicenter, open label Phase IIA trial of oral DCA in 40 surgical patients with recurrent GBM who have clinically indicated debulking surgery planned. No patients will be recruited at UF.
- Trial name
- NCT05120284
- Testing
- Dichloroacetate (DCA), Genotype
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of Florida
Brain, Cancer
A Ketogenic Diet as a Complementary Treatment on Patients With High-grade Gliomas and Brain Metastases
The survival interval of patients with gliomas ranges between 12 to 15 months. Recent findings revealed that dietary interventions to reduce glucose and glycolytic pathways could have a therapeutic effect.
- Trial name
- NCT05564949
- Testing
- CKD
- Where
- 2 sites in Greece
- Volunteers
- 15 people
- Sponsor
- Attikon Hospital
Neuroblastoma
Combination Chemotherapy in Treating Young Patients Who Are Undergoing Surgery and an Autologous Bone Marrow Transplant for Disseminated Neuroblastoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00365755
- Testing
- carboplatin, cisplatin, cyclophosphamide
- Sponsor
- Children's Cancer and Leukaemia Group
Brain Tumor
Disease Progression and Treatment-induced Alterations in Glioblastoma
Summary of scientific evidence and rationale of this project: Integrative molecular-genetic approaches have provided important insights in the biology of glioblastoma.
- Trial name
- NCT02152748
- Testing
- analyze systematically morphological and molecular changes associated with glioblastoma progression and therapy-resistance
- Where
- Austria
- Volunteers
- 60 people
- Sponsor
- Medical University of Vienna
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.